次世代婦人科がん診断薬の世界市場レポート 2025年

次世代婦人科がん診断薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.3％で46億1,000万米ドルに成長します。予測期間の成長は、精密医療と標的治療、人工知能（AI）の統合、リキッドバイオプシーの採用、ポイントオブケア検査の拡大、3D画像の普及、がん治療における遠隔医療の台頭などに起因します。予測期間における主な動向には、患者中心の診断、包括的なバイオマーカー・パネル、ウェアラブル機器の統合、共同研究やコンソーシアム、画像診断モダリティの進歩などがあります。

市場の上昇軌道は、子宮頸部、子宮体部、卵巣、卵管、外陰部などの生殖器に影響を及ぼす婦人科悪性腫瘍の発生率の上昇に大きく影響されています。次世代婦人科がん診断薬は、がん細胞の早期発見を通じてこれらの悪性腫瘍に対処し、標的治療を促進し、最終的に患者の転帰全体を改善するのに役立っています。2023年2月の時点で、米国国立がん研究所は、13,960人の米国人女性が進行性の子宮頸がんの診断に直面し、同年に4,310人が死亡すると予測しています。これらの数字は、女性10万人あたり年間7.7人が新たに発症し、女性10万人あたり年間2.2人が死亡するという、高度な診断ソリューションの緊急の必要性を強調しています。その結果、婦人科悪性腫瘍の有病率の上昇は、次世代婦人科がん診断薬市場の成長を促進する大きな要因となっています。

婦人科がん診断市場の成長は、個別化医療の採用増加によって促進されると予測されています。この革新的なヘルスケアアプローチは、患者一人ひとりの特性に合わせた治療や介入を行うものです。個別化医療は、個々の遺伝的・分子的変異を考慮することで精密診断を強化し、より正確で的を絞った治療につながります。このアプローチは治療効果を予測するだけでなく、副作用を軽減し、遺伝的素因の早期発見を可能にします。2022年、米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）は37の新規分子化合物（NME）を承認したが、そのうち約34％（12件）は個別化医療連合（PMC）によって個別化医薬品に分類されました。その結果、個別化医療の普及が次世代婦人科がん診断薬市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界次世代婦人科がん診断薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の次世代婦人科がん診断薬市場：成長率分析
• 世界の次世代婦人科がん診断薬市場の実績：規模と成長, 2019-2024
• 世界の次世代婦人科がん診断薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界次世代婦人科がん診断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の次世代婦人科がん診断薬市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子宮頸がん
• 卵巣がん
• 子宮がん
• 膣がん
• 外陰がん
• 世界の次世代婦人科がん診断薬市場：機能別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療モニタリング
• コンパニオン診断
• 予測
• がん検診
• リスク分析
• 世界の次世代婦人科がん診断薬市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 次世代シーケンシング
• qPCRとマルチプレックス
• ラボオンチップ（LOAC）と逆転写PCR（RT-PCR）
• タンパク質マイクロアレイ
• DNAマイクロアレイ
• 世界の次世代婦人科がん診断薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオマーカー開発
• CTC分析
• プロテオーム解析
• エピジェネティック解析
• 遺伝子解析
• 世界の次世代婦人科がん診断薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院および外来センター
• 診断検査室
• 学術研究機関
• 世界の次世代婦人科がん診断薬市場子宮頸がんの種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• HPV検査
• パップスメア検査
• 液状細胞診
• バイオマーカー検査
• 世界の次世代婦人科がん診断薬市場卵巣がんの種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• CA-125検査
• HE4テスト
• 遺伝子検査（BRCA1またはBRCA2）
• イメージング技術
• 世界の次世代婦人科がん診断薬市場子宮がんの種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子宮内膜生検
• 超音波画像診断
• 遺伝子検査（PMS2、MLH1）
• バイオマーカー検査
• 世界の次世代婦人科がん診断薬市場膣がんの種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• パップスメア検査
• HPV検査
• 生検手順
• 世界の次世代婦人科がん診断薬市場外陰がんの種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 目視検査
• 生検
• HPV検査
• 遺伝子検査

第7章 地域別・国別分析

• 世界の次世代婦人科がん診断薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の次世代婦人科がん診断薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 次世代婦人科がん診断薬市場：競合情勢
• 次世代婦人科がん診断薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthcare GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Agena Bioscience Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Koninklijke Philips N.V.
• Becton, Dickinson and Company
• GE HealthCare Technologies Inc.
• Laboratory Corporation Of America Holdings
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Hologic Inc.
• Illumina Inc.
• PerkinElmer Inc.
• Sysmex Corporation
• Qiagen N.V.
• ARUP Laboratories
• Almac Group
• BGI Genomics Co Ltd
• OPKO HEALTH Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 次世代婦人科がん診断薬市場2029：新たな機会を提供する国
• 次世代婦人科がん診断薬市場2029：新たな機会を提供するセグメント
• 次世代婦人科がん診断薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Next-generation gynecological cancer diagnostics encompass advanced and innovative methods aimed at the early detection, accurate diagnosis, and personalized treatment of cancers originating in a woman's reproductive organs. These cancers arise in specific areas of the pelvis, which is the region below the stomach and between the hip bones. This approach focuses on improving patient outcomes by enabling personalized treatment plans and targeted therapies based on precise biomarker analysis.

The primary types of next-generation gynecological cancers comprise cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, and vulvar cancer. Cervical cancer specifically occurs in the cells of the cervix, the lower segment of the uterus. Various diagnostic functions are performed, including therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. These functions utilize a range of technologies such as next-generation sequencing, QPCR and multiplexing, lab-on-a-chip (LOAC), reverse transcriptase-PCR (RT-PCR), protein microarrays, and DNA microarrays. Applications of these technologies span biomarker development, circulating tumor cell (CTC) analysis, proteomic analysis, epigenetic analysis, and genetic analysis. The end users of these diagnostics encompass hospitals and ambulatory centers, diagnostic laboratories, and academic and research institutes.

The next-generation gynecological cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides next-generation gynecological cancer diagnostics market statistics, including next-generation gynecological cancer diagnostics industry global market size, regional shares, competitors with a next-generation gynecological cancer diagnostics market share, detailed next-generation gynecological cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation gynecological cancer diagnostics industry. This next-generation gynecological cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation gynecological cancer diagnostics market size has grown rapidly in recent years. It will grow from $2.7 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to advancements in genomic research, increased awareness and screening programs, rising incidence of gynecological cancers, improvements in biopsy techniques, clinical trials, and research funding

The next-generation gynecological cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to precision medicine and targeted therapies, integration of artificial intelligence (AI), liquid biopsy adoption, expansion of point-of-care testing, widespread implementation of 3d imaging, rise of telemedicine in cancer care. Major trends in the forecast period include patient-centric diagnostics, comprehensive biomarker panels, integration of wearable devices, collaborations and consortia, and advances in imaging modalities.

The upward trajectory of the market is significantly influenced by the rising incidence of gynecological malignancies, affecting reproductive organs such as the cervix, uterus, ovaries, fallopian tubes, and vulva. Next-generation gynecological cancer diagnostics are instrumental in addressing these malignancies through early cancer cell detection, facilitating targeted treatments, and ultimately improving overall patient outcomes. As of February 2023, the National Cancer Institute projected that 13,960 American women would face an aggressive cervical cancer diagnosis, with an expected 4,310 fatalities in the same year. These figures underscore the urgent need for advanced diagnostic solutions, with an annual incidence of 7.7 new cases per 100,000 women and an annual death rate of 2.2 per 100,000 females. Consequently, the rising prevalence of gynecological malignancies serves as a substantial driver propelling the growth of the next-generation gynecological cancer diagnostics market.

The growth of the gynecological cancer diagnostics market is anticipated to be fueled by the increasing adoption of personalized medicine. This innovative healthcare approach tailors medical treatment and interventions to the unique characteristics of each patient. Personalized medicine enhances precision diagnosis by considering individual genetic and molecular variations, leading to more accurate and targeted therapies. This approach not only predicts treatment responses but also reduces adverse effects and enables early detection of genetic predispositions. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Consequently, the growing adoption of personalized medicine emerges as a driving force behind the expansion of the next-generation gynecological cancer diagnostics market.

Leading companies in the next-generation gynecological cancer diagnostics market are actively innovating by introducing cutting-edge products, such as AI-enabled women's health ultrasound systems, to secure a competitive advantage. Ultrasound systems are pivotal medical imaging devices that utilize high-frequency sound waves to generate visual representations of internal body structures. For example, in February 2023, Samsung Electronics Co. Ltd., a South Korea-based consumer electronics giant, launched the HERA W10 Elite. This women's health ultrasound system incorporates artificial intelligence (AI) tools and clinical applications tailored for Obstetrics and Gynecology. The HERA W10 Elite delivers advanced 2D and 3D visualizations of microcirculatory and slow blood, featuring an Advanced MV-Flow capability, a larger organic light-emitting diode (OLED) display, and enhanced AI capabilities such as HeartAssist, ViewAssist, and BiometryAssist. Engineered for enhanced diagnostic insights, the HERA W10 Elite aims to revolutionize Obstetrics and Gynecology through sophisticated image processing and an ergonomic-friendly design.

Major players in the gynecological cancer diagnostics market are strategically developing novel products such as cervical cancer vaccines to stay ahead in the competitive landscape. Vaccines are biological preparations that confer active acquired immunity to specific diseases. For instance, in July 2023, Serum Institute of India Pvt. Ltd., a prominent Indian biotechnology company, introduced Cervavac, the nation's first domestically-produced vaccine providing protection against cervical cancer. Cervavac guards against the Human Papilloma Virus (HPV), the primary cause of cervical cancer, and is accessible to both men and women. Operating prophylactically, Cervavac stimulates the immune system to prevent HPV infection, offering cross-protection against multiple high-risk HPV types. With proven efficacy against HPV types 16 and 18, Cervavac is priced affordably at 200 to 400 rupees (approximately $2.50 to $5), ensuring accessibility, particularly for marginalized communities. This initiative contributes to making cervical cancer prevention more cost-effective in India.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition is intended to strengthen Pfizer's oncology portfolio, with a particular emphasis on developing innovative cancer therapies. The deal underscores Pfizer's dedication to expanding its capabilities in cancer treatment by utilizing Seagen's expertise and technologies within the oncology field. Seagen Inc. is a US-based company that specializes in antibody-drug conjugate-based targeted therapeutics for gynecological cancers.

Major companies operating in the next-generation gynecological cancer diagnostics market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Agena Bioscience Inc., Koninklijke Philips N.V., Becton, Dickinson and Company, GE HealthCare Technologies Inc., Laboratory Corporation Of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Qiagen N.V., ARUP Laboratories, Almac Group, BGI Genomics Co Ltd, OPKO HEALTH Inc., BGI Genomics Co. Ltd., Myriad Genetics Inc., Fulgent Genetics Inc., Cepheid, Invitae Corporation, Centogene NV

North America was the largest region in the next-generation gynecological cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation gynecological cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the next-generation gynecological cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation gynecological cancer diagnostics market includes revenues earned by entities by providing blood tests, next-generation sequencing, imaging tests, biopsy and pathology, minimally invasive procedures, personalized medicine, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next-Generation Gynecological Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next-generation gynecological cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next-generation gynecological cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next-generation gynecological cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Cervical Cancer; Ovarian Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
• 2) By Function: Therapeutic Monitoring; Companion Diagnostics; Prognostics; Cancer Screening; Risk Analysis
• 3) By Technology: Next-Generation Sequencing; qPCR And Multiplexing; Lab-on- A- Chip (LOAC) And Reverse Transcriptase-PCR (RT-PCR); Protein Microarrays; DNA Microarrays
• 4) By Application: Biomarker Development; CTC Analysis; Proteomic Analysis; Epigenetic Analysis; Genetic Analysis
• 5) By End User: Hospitals And Ambulatory Centers; Diagnostic Laboratories; Academic And Research Institutes
• Subsegments:
• 1) By Cervical Cancer: HPV Testing; Pap Smear Testing; Liquid-Based Cytology; Biomarker Testing
• 2) By Ovarian Cancer: CA-125 Testing; HE4 Testing; Genetic Testing (BRCA1 Or BRCA2); Imaging Techniques
• 3) By Uterine Cancer: Endometrial Biopsy; Ultrasound Imaging; Genetic Testing (PMS2, MLH1); Biomarker Testing
• 4) By Vaginal Cancer: Pap Smear Testing; HPV Testing; Biopsy Procedures
• 5) By Vulvar Cancer: Visual Inspection; Biopsy; HPV Testing; Genetic Testing
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthcare GmbH; Agena Bioscience Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next-Generation Gynecological Cancer Diagnostics Market Characteristics

3. Next-Generation Gynecological Cancer Diagnostics Market Trends And Strategies

4. Next-Generation Gynecological Cancer Diagnostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Next-Generation Gynecological Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next-Generation Gynecological Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next-Generation Gynecological Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next-Generation Gynecological Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next-Generation Gynecological Cancer Diagnostics Total Addressable Market (TAM)

6. Next-Generation Gynecological Cancer Diagnostics Market Segmentation

• 6.1. Global Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervical Cancer
• Ovarian Cancer
• Uterine Cancer
• Vaginal Cancer
• Vulvar Cancer
• 6.2. Global Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis
• 6.3. Global Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing
• qPCR And Multiplexing
• Lab-on-A-Chip (LOAC) And Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays
• 6.4. Global Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis
• 6.5. Global Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Ambulatory Centers
• Diagnostic Laboratories
• Academic And Research Institutes
• 6.6. Global Next-Generation Gynecological Cancer Diagnostics Market, Sub-Segmentation Of Cervical Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HPV Testing
• Pap Smear Testing
• Liquid-Based Cytology
• Biomarker Testing
• 6.7. Global Next-Generation Gynecological Cancer Diagnostics Market, Sub-Segmentation Of Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CA-125 Testing
• HE4 Testing
• Genetic Testing (BRCA1 Or BRCA2)
• Imaging Techniques
• 6.8. Global Next-Generation Gynecological Cancer Diagnostics Market, Sub-Segmentation Of Uterine Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endometrial Biopsy
• Ultrasound Imaging
• Genetic Testing (PMS2, MLH1)
• Biomarker Testing
• 6.9. Global Next-Generation Gynecological Cancer Diagnostics Market, Sub-Segmentation Of Vaginal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pap Smear Testing
• HPV Testing
• Biopsy Procedures
• 6.10. Global Next-Generation Gynecological Cancer Diagnostics Market, Sub-Segmentation Of Vulvar Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Visual Inspection
• Biopsy
• HPV Testing
• Genetic Testing

7. Next-Generation Gynecological Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Next-Generation Gynecological Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next-Generation Gynecological Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market

• 8.1. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next-Generation Gynecological Cancer Diagnostics Market

• 9.1. China Next-Generation Gynecological Cancer Diagnostics Market Overview
• 9.2. China Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next-Generation Gynecological Cancer Diagnostics Market

• 10.1. India Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next-Generation Gynecological Cancer Diagnostics Market

• 11.1. Japan Next-Generation Gynecological Cancer Diagnostics Market Overview
• 11.2. Japan Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next-Generation Gynecological Cancer Diagnostics Market

• 12.1. Australia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next-Generation Gynecological Cancer Diagnostics Market

• 13.1. Indonesia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next-Generation Gynecological Cancer Diagnostics Market

• 14.1. South Korea Next-Generation Gynecological Cancer Diagnostics Market Overview
• 14.2. South Korea Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next-Generation Gynecological Cancer Diagnostics Market

• 15.1. Western Europe Next-Generation Gynecological Cancer Diagnostics Market Overview
• 15.2. Western Europe Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next-Generation Gynecological Cancer Diagnostics Market

• 16.1. UK Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next-Generation Gynecological Cancer Diagnostics Market

• 17.1. Germany Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next-Generation Gynecological Cancer Diagnostics Market

• 18.1. France Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next-Generation Gynecological Cancer Diagnostics Market

• 19.1. Italy Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next-Generation Gynecological Cancer Diagnostics Market

• 20.1. Spain Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next-Generation Gynecological Cancer Diagnostics Market

• 21.1. Eastern Europe Next-Generation Gynecological Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next-Generation Gynecological Cancer Diagnostics Market

• 22.1. Russia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next-Generation Gynecological Cancer Diagnostics Market

• 23.1. North America Next-Generation Gynecological Cancer Diagnostics Market Overview
• 23.2. North America Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next-Generation Gynecological Cancer Diagnostics Market

• 24.1. USA Next-Generation Gynecological Cancer Diagnostics Market Overview
• 24.2. USA Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next-Generation Gynecological Cancer Diagnostics Market

• 25.1. Canada Next-Generation Gynecological Cancer Diagnostics Market Overview
• 25.2. Canada Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next-Generation Gynecological Cancer Diagnostics Market

• 26.1. South America Next-Generation Gynecological Cancer Diagnostics Market Overview
• 26.2. South America Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next-Generation Gynecological Cancer Diagnostics Market

• 27.1. Brazil Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next-Generation Gynecological Cancer Diagnostics Market

• 28.1. Middle East Next-Generation Gynecological Cancer Diagnostics Market Overview
• 28.2. Middle East Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next-Generation Gynecological Cancer Diagnostics Market

• 29.1. Africa Next-Generation Gynecological Cancer Diagnostics Market Overview
• 29.2. Africa Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next-Generation Gynecological Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next-Generation Gynecological Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Next-Generation Gynecological Cancer Diagnostics Market Competitive Landscape
• 30.2. Next-Generation Gynecological Cancer Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Siemens Healthcare GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Agena Bioscience Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Next-Generation Gynecological Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Koninklijke Philips N.V.
• 31.2. Becton, Dickinson and Company
• 31.3. GE HealthCare Technologies Inc.
• 31.4. Laboratory Corporation Of America Holdings
• 31.5. Quest Diagnostics Incorporated
• 31.6. Agilent Technologies Inc.
• 31.7. Hologic Inc.
• 31.8. Illumina Inc.
• 31.9. PerkinElmer Inc.
• 31.10. Sysmex Corporation
• 31.11. Qiagen N.V.
• 31.12. ARUP Laboratories
• 31.13. Almac Group
• 31.14. BGI Genomics Co Ltd
• 31.15. OPKO HEALTH Inc.

32. Global Next-Generation Gynecological Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next-Generation Gynecological Cancer Diagnostics Market

34. Recent Developments In The Next-Generation Gynecological Cancer Diagnostics Market

35. Next-Generation Gynecological Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Next-Generation Gynecological Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next-Generation Gynecological Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next-Generation Gynecological Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer